MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The medicine was well tolerated, with no unexpected safety issue
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Triggering global regulatory submissions this year for the treatment of obesity
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Subscribe To Our Newsletter & Stay Updated